Stéphane Bancel, Moderna CEO (Hollie Adams/Bloomberg via Getty Images)
May 31, 2024 11:00 AM EDT
Pharma
FDA+

FDA ap­proves Mod­er­na's RSV vac­cine, mark­ing its sec­ond com­mer­cial prod­uct

Max Gelman

Senior Editor

Mod­er­na on Fri­day se­cured a long-await­ed but ex­pect­ed ap­proval for its RSV vac­cine, giv­ing the biotech its first FDA ap­proval for a non-Covid-19 prod­uct and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times